866-997-4948(US-Canada Toll Free)

Fallopian Tube Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 314 Pages

Fallopian Tube Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Fallopian Tube Cancer - Pipeline Review, H2 2014, provides an overview of the Fallopian Tube Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fallopian Tube Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fallopian Tube Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Fallopian Tube Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Fallopian Tube Cancer - Overview 10
Pipeline Products for Fallopian Tube Cancer - Comparative Analysis 11
Fallopian Tube Cancer - Therapeutics under Development by Companies 12
Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 16
Fallopian Tube Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Fallopian Tube Cancer - Products under Development by Companies 19
Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 22
Fallopian Tube Cancer - Companies Involved in Therapeutics Development 23
Johnson & Johnson 23
Boehringer Ingelheim GmbH 24
F. Hoffmann-La Roche Ltd. 25
Amgen Inc. 26
Eli Lilly and Company 27
GlaxoSmithKline plc 28
MedImmune, LLC 29
Daiichi Sankyo Company, Limited 30
Oxford BioMedica plc 31
Millennium Pharmaceuticals, Inc. 32
Novartis AG 33
Astellas Pharma Inc. 34
ImmunoGen, Inc. 35
Astex Pharmaceuticals, Inc. 36
CTI BioPharma Corp. 37
Bayer AG 38
Incyte Corporation 39
Active Biotech AB 40
Oncolytics Biotech Inc. 41
OXiGENE, Inc. 42
Curis, Inc. 43
Topotarget A/S 44
NeoStem, Inc. 45
Pharmacyclics, Inc. 46
Synta Pharmaceuticals Corp. 47
Oasmia Pharmaceutical AB 48
MabVax Therapeutics, Inc. 49
Acceleron Pharma, Inc. 50
Cerulean Pharma, Inc. 51
OncoMed Pharmaceuticals, Inc. 52
TetraLogic Pharmaceuticals 53
Merrimack Pharmaceuticals, Inc. 54
Immunovaccine, Inc. 55
Pharma Mar, S.A. 56
VentiRx Pharmaceuticals, Inc. 57
TRACON Pharmaceuticals, Inc. 58
Lee's Pharmaceutical Holdings Limited 59
Clovis Oncology, Inc. 60
Recepta Biopharma S.A. 61
EGEN, Inc. 62
Sanofi Pasteur SA 63
AbbVie Inc. 64
Fallopian Tube Cancer - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 71
Assessment by Route of Administration 75
Assessment by Molecule Type 77
Drug Profiles 79
pazopanib hydrochloride - Drug Profile 79
trebananib - Drug Profile 83
paclitaxel poliglumex - Drug Profile 86
paclitaxel - Drug Profile 90
binimetinib - Drug Profile 92
bevacizumab - Drug Profile 96
trabectedin - Drug Profile 101
rucaparib phosphate - Drug Profile 104
alisertib - Drug Profile 107
SGI-110 - Drug Profile 111
abiraterone acetate - Drug Profile 113
tasquinimod - Drug Profile 116
dalantercept - Drug Profile 118
elesclomol - Drug Profile 120
belinostat - Drug Profile 122
TroVax - Drug Profile 125
ramucirumab - Drug Profile 128
SG-2000 - Drug Profile 133
pelareorep - Drug Profile 135
nintedanib - Drug Profile 139
CRLX-101 - Drug Profile 142
VTX-2337 - Drug Profile 144
gimatecan - Drug Profile 146
seribantumab - Drug Profile 148
exatecan mesylate - Drug Profile 151
TRC-105 - Drug Profile 153
RebmAb-100 - Drug Profile 155
EGEN-001 - Drug Profile 157
NSC-748933 - Drug Profile 159
INCB-24360 - Drug Profile 160
birinapant - Drug Profile 162
Cancer Stem Cell Therapy - Drug Profile 164
DPX-Survivac - Drug Profile 165
linsitinib - Drug Profile 168
CDX-1401 - Drug Profile 170
ganetespib - Drug Profile 172
demcizumab - Drug Profile 176
fosbretabulin tromethamine - Drug Profile 179
BNC-105P - Drug Profile 183
Cell Therapy Targeting NY-ESO-1 and LAGE-1 for Cancer - Drug Profile 185
birinapant + conatumumab - Drug Profile 187
CUDC-427 - Drug Profile 189
abexinostat hydrochloride - Drug Profile 190
nintedanib - Drug Profile 192
vCP-2292 - Drug Profile 195
OC-DC Vaccine - Drug Profile 196
IMGN-853 - Drug Profile 197
ABT-767 - Drug Profile 198
anetumab ravtansine - Drug Profile 199
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 201
Fallopian Tube Cancer - Recent Pipeline Updates 202
Fallopian Tube Cancer - Dormant Projects 302
Fallopian Tube Cancer - Discontinued Products 303
Fallopian Tube Cancer - Product Development Milestones 304
Featured News & Press Releases 304
Appendix 310
Methodology 310
Coverage 310
Secondary Research 310
Primary Research 310
Expert Panel Validation 310
Contact Us 311
Disclaimer 311

List of Tables
Number of Products under Development for Fallopian Tube Cancer, H2 2014 13
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Development by Companies, H2 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2014 19
Comparative Analysis by Late Stage Development, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Development by Companies, H2 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2014 25
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2014 26
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 27
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 28
Fallopian Tube Cancer - Pipeline by Amgen Inc., H2 2014 29
Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H2 2014 30
Fallopian Tube Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 31
Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H2 2014 32
Fallopian Tube Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 33
Fallopian Tube Cancer - Pipeline by Oxford BioMedica plc, H2 2014 34
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 35
Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2014 36
Fallopian Tube Cancer - Pipeline by Astellas Pharma Inc., H2 2014 37
Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H2 2014 38
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 39
Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H2 2014 40
Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2014 41
Fallopian Tube Cancer - Pipeline by Incyte Corporation, H2 2014 42
Fallopian Tube Cancer - Pipeline by Active Biotech AB, H2 2014 43
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 44
Fallopian Tube Cancer - Pipeline by OXiGENE, Inc., H2 2014 45
Fallopian Tube Cancer - Pipeline by Curis, Inc., H2 2014 46
Fallopian Tube Cancer - Pipeline by Topotarget A/S, H2 2014 47
Fallopian Tube Cancer - Pipeline by NeoStem, Inc., H2 2014 48
Fallopian Tube Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 49
Fallopian Tube Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 50
Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 51
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics, Inc., H2 2014 52
Fallopian Tube Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 53
Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 54
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 55
Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 56
Fallopian Tube Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 57
Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H2 2014 58
Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H2 2014 59
Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 60
Fallopian Tube Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 61
Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 62
Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 63
Fallopian Tube Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 64
Fallopian Tube Cancer - Pipeline by EGEN, Inc., H2 2014 65
Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2014 66
Fallopian Tube Cancer - Pipeline by AbbVie Inc., H2 2014 67
Assessment by Monotherapy Products, H2 2014 68
Assessment by Combination Products, H2 2014 69
Number of Products by Stage and Target, H2 2014 72
Number of Products by Stage and Mechanism of Action, H2 2014 76
Number of Products by Stage and Route of Administration, H2 2014 79
Number of Products by Stage and Molecule Type, H2 2014 81
Fallopian Tube Cancer Therapeutics - Recent Pipeline Updates, H2 2014 205
Fallopian Tube Cancer - Dormant Projects, H2 2014 305
Fallopian Tube Cancer - Discontinued Products, H2 2014 306

List of Figures
Number of Products under Development for Fallopian Tube Cancer, H2 2014 13
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Assessment by Monotherapy Products, H2 2014 68
Number of Products by Top 10 Target, H2 2014 70
Number of Products by Stage and Top 10 Target, H2 2014 71
Number of Products by Top 10 Mechanism of Action, H2 2014 74
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 75
Number of Products by Top 10 Route of Administration, H2 2014 78
Number of Products by Stage and Top 10 Route of Administration, H2 2014 79
Number of Products by Top 10 Molecule Type, H2 2014 80
Number of Products by Stage and Top 10 Molecule Type, H2 2014 81

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *